 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || zilebesiran (ALN-AGT) / Alnylam, Roche
Review, Journal: Will zilebesiran, an RNA interference therapy, be effective, safe, and improve the treatment of hypertension? (Pubmed Central) - Dec 4, 2024
It was also difficult to reliably interpret the results of KARDIA-1 as blood pressure went up significantly in the placebo group. KARDIA-1 did not answer previous concerns about zilebesiran; (i) what happens during volume depletion, sepsis, and pregnancy when angiotensinogen is inhibited long-term or (ii) will it be effective in a high sodium diet.
- zilebesiran (ALN-AGT) / Alnylam, Roche, IONIS-AGT-LRx / Ionis
Injectable angiotensinogen inhibition therapy for hypertension: a systematic review and meta-analysis (Station 7 - Research Gateway) - May 14, 2024 - Abstract #ESC2024ESC_4571;
Conclusions In this meta-analysis of RCTs, injectable AGT inhibitors were associated with a significant decrease in mean AGT, SBP, and DBP as compared with placebo. There were no significant differences between groups in serious adverse events, although injection site reaction was more common in patients treated with injectable AGT inhibitors.
- | IONIS-AGT-LRx / Ionis
As for competitors, still can't see any detail on $IONS IONIS-AGT-LRx or ION904 data $ALNY $RHHBY https://t.co/WWA9kivB6Y (Twitter) - Jul 25, 2023
- ||| IONIS-AGT-LRx / Ionis
Trial completion: ASTRAAS: A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx in Hypertensive Participants With Uncontrolled Blood Pressure (clinicaltrials.gov) - Feb 27, 2023
P2, N=160, Completed, Sponsor: Ionis Pharmaceuticals, Inc.
There were no significant differences between groups in serious adverse events, although injection site reaction was more common in patients treated with injectable AGT inhibitors. Active, not recruiting --> Completed
- ||| IONIS-AGT-LRx / Ionis
Trial completion: ASTRAAS-HF: A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx in Participants With Chronic Heart Failure With Reduced Ejection Fraction (clinicaltrials.gov) - Feb 21, 2023
P2, N=72, Completed, Sponsor: Ionis Pharmaceuticals, Inc.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | IONIS-AGT-LRx / Ionis
Trial completion date: ASTRAAS: A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx in Hypertensive Participants With Uncontrolled Blood Pressure (clinicaltrials.gov) - Aug 8, 2022
P2, N=136, Active, not recruiting, Sponsor: Ionis Pharmaceuticals, Inc.
Active, not recruiting --> Completed Trial completion date: Jan 2023 --> Sep 2022
- || IONIS-AGT-LRx / Ionis
Enrollment closed: ASTRAAS-HF: A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx in Participants With Chronic Heart Failure With Reduced Ejection Fraction (clinicaltrials.gov) - Jul 28, 2022
P2, N=72, Active, not recruiting, Sponsor: Ionis Pharmaceuticals, Inc.
Trial completion date: Jan 2023 --> Sep 2022 Recruiting --> Active, not recruiting
- || IONIS-AGT-LRx / Ionis
Enrollment closed: ASTRAAS: A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx in Hypertensive Participants With Uncontrolled Blood Pressure (clinicaltrials.gov) - Mar 28, 2022
P2, N=136, Active, not recruiting, Sponsor: Ionis Pharmaceuticals, Inc.
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- || IONIS-AGT-LRx / Ionis
Trial completion date, Trial primary completion date: ASTRAAS: A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx in Hypertensive Participants With Uncontrolled Blood Pressure (clinicaltrials.gov) - Feb 17, 2022
P2, N=150, Recruiting, Sponsor: Ionis Pharmaceuticals, Inc.
Recruiting --> Active, not recruiting Trial completion date: May 2022 --> Jan 2023 | Trial primary completion date: May 2022 --> Oct 2022
- | IONIS-AGT-LRx / Ionis
Trial completion date: ASTRAAS-HF: A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx in Participants With Chronic Heart Failure With Reduced Ejection Fraction (clinicaltrials.gov) - Feb 9, 2022
P2, N=72, Recruiting, Sponsor: Ionis Pharmaceuticals, Inc.
Trial completion date: May 2022 --> Jan 2023 | Trial primary completion date: May 2022 --> Oct 2022 Trial completion date: Sep 2022 --> Jan 2023
- || IONIS-AGT-LRx / Ionis
Clinical, P1 data, P2 data, Journal: Antisense Inhibition of Angiotensinogen With IONIS-AGT-L: Results of Phase 1 and Phase 2 Studies. (Pubmed Central) - Jul 6, 2021
P1, P2
In conclusion, IONIS-AGT-L significantly reduces AGT with a favorable safety, tolerability, and on-target profile. (A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx; NCT04083222; A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx, an Antisense Inhibitor Administered Subcutaneously to Hypertensive Subjects With Controlled Blood Pressure; NCT03714776; Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ionis AGT-LRx in Healthy Volunteers; NCT03101878).
- ||| IONIS-AGT-LRx / Ionis
Enrollment open: ASTRAAS-HF: A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx in Participants With Chronic Heart Failure With Reduced Ejection Fraction (clinicaltrials.gov) - Apr 13, 2021
P2, N=72, Recruiting, Sponsor: Ionis Pharmaceuticals, Inc.
(A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx; NCT04083222; A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx, an Antisense Inhibitor Administered Subcutaneously to Hypertensive Subjects With Controlled Blood Pressure; NCT03714776; Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ionis AGT-LRx in Healthy Volunteers; NCT03101878). Not yet recruiting --> Recruiting
- |||| IONIS-AGT-LRx / Ionis
New P2 trial: ASTRAAS-HF: A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx in Participants With Chronic Heart Failure With Reduced Ejection Fraction (clinicaltrials.gov) - Apr 7, 2021
P2, N=72, Not yet recruiting, Sponsor: Ionis Pharmaceuticals, Inc.
- ||| IONIS-AGT-LRx / Ionis
Enrollment open: ASTRAAS: A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx in Hypertensive Participants With Uncontrolled Blood Pressure (clinicaltrials.gov) - Mar 3, 2021
P2, N=150, Recruiting, Sponsor: Ionis Pharmaceuticals, Inc.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- IONIS-AGT-LRx / Ionis
[VIRTUAL] EFFECT OF IONIS-AGT-LRX, AN ANTISENSE INHIBITOR OF ANGIOTENSINOGEN PRODUCTION, IN HEALTHY VOLUNTEERS AND IN SUBJECTS WITH HYPERTENSION: RESULTS OF PHASE 1 AND PHASE 2 STUDIES (eAbstract site) - Feb 17, 2021 - Abstract #ACC2021ACC_3749;
IONIS-AGT-LRX results in significant AGT reductions with favorable safety and tolerability profile. As monotherapy, proof of principle was demonstrated as evidenced by reduction in SBP thereby providing support to proceed to larger phase 2 trials in patients with resistant hypertension and heart failure.
- IONIS-AGT-LRx / Ionis
[VIRTUAL] EFFECT OF IONIS-AGT-LRX IN SUBJECTS WITH UNCONTROLLED HYPERTENSION ON 2-3 MEDICATIONS: RESULTS OF A PHASE 2 STUDY (eAbstract site) - Feb 17, 2021 - Abstract #ACC2021ACC_3748;
No on-target effects were observed. A dose-ranging, Ph2B study is underway in subjects with resistant HTN on ≥ 3 meds, as well a Ph2 study in patients with heart failure with reduced ejection fraction.
- |||| IONIS-AGT-LRx / Ionis
New P2 trial: ASTRAAS: A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx in Hypertensive Participants With Uncontrolled Blood Pressure (clinicaltrials.gov) - Jan 18, 2021
P2, N=150, Not yet recruiting, Sponsor: Ionis Pharmaceuticals, Inc.
- || IONIS-AGT-LRx / Ionis
Trial completion, Trial completion date: A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx (clinicaltrials.gov) - Sep 15, 2020
P2, N=26, Completed, Sponsor: Ionis Pharmaceuticals, Inc.
A dose-ranging, Ph2B study is underway in subjects with resistant HTN on ≥ 3 meds, as well a Ph2 study in patients with heart failure with reduced ejection fraction. Active, not recruiting --> Completed | Trial completion date: Jan 2021 --> Jul 2020
- | IONIS-AGT-LRx / Ionis
Enrollment closed: A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx (clinicaltrials.gov) - Apr 28, 2020
P2, N=26, Active, not recruiting, Sponsor: Ionis Pharmaceuticals, Inc.
Active, not recruiting --> Completed | Trial completion date: Jan 2021 --> Jul 2020 Recruiting --> Active, not recruiting
- || IONIS-AGT-LRx / Ionis
Trial completion: A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx, an Antisense Inhibitor Administered Subcutaneously to Hypertensive Participants With Controlled Blood Pressure (clinicaltrials.gov) - Feb 13, 2020
P2, N=25, Completed, Sponsor: Ionis Pharmaceuticals, Inc.
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | IONIS-AGT-LRx / Ionis
Enrollment open: A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx (clinicaltrials.gov) - Oct 14, 2019
P2, N=30, Recruiting, Sponsor: Ionis Pharmaceuticals, Inc.
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- | IONIS-AGT-LRx / Ionis
New P2 trial: A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx (clinicaltrials.gov) - Sep 9, 2019
P2, N=30, Not yet recruiting, Sponsor: Ionis Pharmaceuticals, Inc.
- | IONIS-AGT-LRx / Ionis
Enrollment closed: A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx, an Antisense Inhibitor Administered Subcutaneously to Hypertensive Participants With Controlled Blood Pressure (clinicaltrials.gov) - Aug 6, 2019
P2, N=25, Active, not recruiting, Sponsor: Ionis Pharmaceuticals, Inc.
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- || IONIS-AGT-LRx / Ionis
Enrollment open: A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx, an Antisense Inhibitor Administered Subcutaneously to Hypertensive Participants With Controlled Blood Pressure (clinicaltrials.gov) - Mar 25, 2019
P2, N=30, Recruiting, Sponsor: Ionis Pharmaceuticals, Inc.
Recruiting --> Active, not recruiting Active, not recruiting --> Recruiting
- | IONIS-AGT-LRx / Ionis
Enrollment closed, Trial primary completion date: A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx, an Antisense Inhibitor Administered Subcutaneously to Hypertensive Participants With Controlled Blood Pressure (clinicaltrials.gov) - Feb 27, 2019
P2, N=30, Active, not recruiting, Sponsor: Ionis Pharmaceuticals, Inc.
Active, not recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2019 --> Jan 2020
- || IONIS-AGT-LRx / Ionis
Enrollment open: A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx, an Antisense Inhibitor Administered Subcutaneously to Hypertensive Participants With Controlled Blood Pressure (clinicaltrials.gov) - Dec 6, 2018
P2, N=30, Recruiting, Sponsor: Ionis Pharmaceuticals, Inc.
Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2019 --> Jan 2020 Not yet recruiting --> Recruiting
- | IONIS-AGT-LRx / Ionis
New P2 trial: A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx, an Antisense Inhibitor Administered Subcutaneously to Hypertensive Participants With Controlled Blood Pressure (clinicaltrials.gov) - Oct 21, 2018
P2, N=30, Not yet recruiting, Sponsor: Ionis Pharmaceuticals, Inc.
- | IONIS-AGT-LRx / Ionis
Trial completion: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ionis AGT-LRx in Healthy Volunteers (clinicaltrials.gov) - Aug 21, 2018
P1, N=62, Completed, Sponsor: Ionis Pharmaceuticals, Inc.
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- || IONIS-AGT-LRx / Ionis
Enrollment closed, Phase classification, Trial completion date, Trial primary completion date: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ionis AGT-LRx in Healthy Volunteers (clinicaltrials.gov) - May 3, 2018
P1, N=62, Active, not recruiting, Sponsor: Ionis Pharmaceuticals, Inc.
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Phase classification: P1/2 --> P1 | Trial completion date: Jan 2019 --> Aug 2018 | Trial primary completion date: Nov 2018 --> May 2018
- || IONIS-AGT-LRx / Ionis
Trial completion date, Trial primary completion date: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ionis AGT-LRx in Healthy Volunteers (clinicaltrials.gov) - Mar 3, 2018
P1/2, N=82, Recruiting, Sponsor: Ionis Pharmaceuticals, Inc.
Recruiting --> Active, not recruiting | Phase classification: P1/2 --> P1 | Trial completion date: Jan 2019 --> Aug 2018 | Trial primary completion date: Nov 2018 --> May 2018 Trial completion date: Dec 2018 --> Jan 2019 | Trial primary completion date: Oct 2018 --> Nov 2018
- ||||| IONIS-AGT-LRx / Ionis
New P1/2 trial: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ionis AGT-LRx in Healthy Volunteers (clinicaltrials.gov) - Apr 5, 2017
P1/2, N=82, Recruiting, Sponsor: Ionis Pharmaceuticals, Inc.